文献速递内脏/肾动脉与血管畸形

移植肾动脉狭窄的血管内治疗:系统综述与荟萃分析

Endovascular Treatment of Transplant Renal Artery Stenosis: A Systematic Review and Meta-analysis.
PubMed 文献 · J Endovasc Ther · 2021-08-16

结果显示血管内治疗可显著降低血清肌酐、血压、用药量及峰值收缩速度,支架组肌酐下降优于单纯PTA,移植物生存率与非TRAS患者相似。总成功率为89%,总并发症率为10.4%,最常见为动脉夹层。

要点

  • 血管内治疗TRAS可显著改善移植肾功能、血压及血流动力学参数。
  • PTA联合支架在稳定肾功能方面优于单纯PTA,并可能降低再狭窄率。
  • 治疗患者与非TRAS患者的移植物生存率相似(HR 0.98,95%CI 0.75-1.28)。

核心结论

  • 血管内治疗TRAS可改善移植物保存、肾功能及血流动力学参数。
  • PTA联合支架在稳定肾功能方面比单纯PTA更有效,并可能降低再狭窄率。

研究设计与样本

  • 遵循PRISMA指南的系统综述与荟萃分析,检索PubMed、Google Scholar、Cochrane和Scopus。

主要发现

  • 支架组血清肌酐下降显著优于对照组,平均差0.68 mg/dL(95%CI 0.17-1.19;Z=2.60,p=0.0009)。
  • 任何干预前后比较显示总体血清肌酐下降0.65 mg/dL(95%CI 0.40-0.90;Z=5.09,p=0.00001)。
  • 总体血压平均下降11.12 mmHg(95%CI 7.29-14.95;Z=5.59,p=0.00001),用药平均差0.77(95%CI 0.29-1.24;p=0.002),峰值收缩速度平均差190.05(95%CI 128.41-251.69;p<0.00001)。
  • 血管内干预与最佳药物治疗比较,血清肌酐平均差0.23 mg/dL(95%CI 0.14-0.32;Z=5.07,p<0.00001), favoring血管内干预。
  • 治疗患者与非TRAS患者移植物生存率相似(风险比0.98;95%CI 0.75-1.28;p=0.091)。

关键数值与推荐

  • 总体汇总成功率为89%,总体并发症率为10.4%,最常见并发症为动脉夹层。

临床怎么用

  • 对于TRAS患者,血管内治疗可考虑用于改善肾功能和血压控制。
  • PTA联合支架可能作为优于单纯PTA的选择,以稳定肾功能并降低再狭窄风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Endovascular treatment through either percutaneous transluminal angioplasty (PTA) alone or stenting has been previously used as a treatment for transplant renal artery stenosis (TRAS). This review aimed to investigate the results of endovascular treatment for renal artery stenosis in transplanted kidneys as compared with the outcomes of interventions, medical management, and graft survival in non-TRAS patients. METHODS: A systematic review of PubMed, Google Scholar, Cochrane, and Scopus was conducted in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines in which studies that reported outcomes of the treatment of TRAS via the endoluminal approach were identified, and their results were meta-analyzed. RESULTS: Fifty-four studies with a total of 1522 patients were included. A significant reduction of serum creatinine level was found, favoring the stenting group, with a mean difference of 0.68 mg/dL (95% confidence interval (CI), 0.17-1.19; Z=2.60, p=0.0009). Comparison of pre- and post-intervention values of any intervention revealed a significant decrease in overall serum creatinine level (0.65 mg/dL; 95% CI, 0.40-0.90; Z=5.09, p=0.00001), overall blood pressure, with a mean difference of 11.12 mmHg (95% CI, 7.29-14.95; Z=5.59, p=0.00001), mean difference in the use of medications (0.77; 95% CI, 0.29-1.24; p=0.002), and peak systolic velocity (190.05; 95% CI, 128.41-251.69; p<0.00001). The comparison of serum creatinine level between endovascular interventions and best medical therapy favored endovascular intervention, with a mean difference of 0.23 mg/dL (95% CI, 0.14-0.32; Z=5.07, p<0.00001). Graft survival was similar between the treated patients and those without TRAS (hazard ratio, 0.98; 95% CI, 0.75-1.28; p=0.091). The overall pooled success rate was 89%, and the overall complication rate was 10.4%, with the most prevalent complication being arterial dissection. CONCLUSION: The endovascular treatment of TRAS improves graft preservation and renal function and hemodynamic parameters. PTA + stenting appears to be a more effective option to PTA alone in the stabilization of renal function, with additional benefits from decreased restenosis rates. Further high-quality studies could expand on these findings.

来源:J Endovasc Ther,查看原文。版权归原作者所有。

引用

  1. Hinojosa-Gonzalez DE, Salgado-Garza G, Torres-Martinez M, et al. Endovascular Treatment of Transplant Renal Artery Stenosis: A Systematic Review and Meta-analysis. J Endovasc Ther. 2021. PMID: 34399594. doi:10.1177/15266028211038593

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。